These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6385487)

  • 1. [Value of Iso Mack Retard in the treatment of coronary disease].
    Zminkowska U; Markiewicz M
    Wiad Lek; 1984 Apr; 37(7):496-500. PubMed ID: 6385487
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iso Mack Retard 40 mg. Coronary drug for long term therapy and prophylaxis in coronary circulation disorders (angina pectoris)].
    Wien Klin Wochenschr; 1980 Oct; 92(19):695-6. PubMed ID: 7467343
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of coronary heart disease. Oxycardin retard in simultaneously existing arterial hypertension].
    Hoffmann J
    Fortschr Med; 1983 Apr; 101(16):764-7. PubMed ID: 6852752
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug therapy of coronary heart disease with nitrisken retard].
    Kugler G; Welzel D; Schiess W
    Ther Ggw; 1982 Mar; 121(3):172-87. PubMed ID: 7046127
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical evaluation of isosorbitol dinitrate (isosorbide dinitrate) in patients with critical stenosis of coronary arteries].
    Podolec P; Pieniazek P; Badacz L; Tracz W
    Pol Tyg Lek; 1984 Jan; 39(1):13-5. PubMed ID: 6377276
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of isonit (nitrosorbide) in the treatment of ischemic heart disease].
    Zamotaev IP; Venediktova MG; Lozinskiĭ LG; Sandomirskiĭ BL
    Klin Med (Mosk); 1986 Jun; 64(6):28-33. PubMed ID: 3747432
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease].
    Smolarz A; Seeliger S; Glocke M
    Med Welt; 1981 Apr; 32(14A):548-53. PubMed ID: 6787385
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term treatment of coronary heart disease with concomitant hypertension. Oxycardin retard in the coronary hypertensive patient].
    Tuluweit K; Strauss G
    ZFA (Stuttgart); 1983 Mar; 59(7):388-94. PubMed ID: 6845862
    [No Abstract]   [Full Text] [Related]  

  • 9. [Coronary disease. Clinical experience with a new active substance combination].
    Bouzo H
    Med Welt; 1977 Dec; 28(49):2001-7. PubMed ID: 340839
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of 50 mg isosorbide-5-nitrate retard on the stress tolerance of patients with coronary heart disease].
    Eggeling T; Jansen W; Osterspey A; Tauchert M; Hilger HH
    Med Klin (Munich); 1986 Apr; 81(8):275-80. PubMed ID: 3785087
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sorbonit in coronary disease].
    Chojnowski JR; Adamska-Dyniewska H; Florczak H; Chojnowska-Jezierska J; Mockallo T
    Pol Tyg Lek; 1968 May; 23(21):797-9. PubMed ID: 4875472
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of IS-5-MN in coronary disease. Monocentric double-blind crossover comparison with ISDN retard and placebo].
    Müller G; Schmidt-Voigt J
    Med Welt; 1981 Apr; 32(14A):554-6. PubMed ID: 7242319
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of nitro-retard preparations during rest and ergometric exercise in patients with coronary heart disease].
    Boutefeu JM; Righetti A; Rutishauser W
    Med Welt; 1980 Aug; 31(35):1251-4. PubMed ID: 7421560
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of the preparation Iso Mack Retard 60 mg I 120 mg in the treatment of patients with advanced ischemic heart disease].
    Markiewicz M; Jach A; Wysokiński A
    Wiad Lek; 1992 Nov; 45(21-22):803-5. PubMed ID: 1299035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term testing of a coronary therapeutic agent under general practice conditions].
    Pascal N
    Med Welt; 1978 Apr; 29(15):635-40. PubMed ID: 417229
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hemodynamic changes during treatment with isodinit, sectral, stenopril and kratemon].
    Stankusheva G; Draganov V; Manolov P
    Vutr Boles; 1987; 26(2):33-8. PubMed ID: 3604194
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of isosorbide dinitrate of prolonged action on the prevention of myocardial ischemia induced by exercise: correlation with nitrate blood levels].
    Duprat R; Meneghelo RS; Batlouni M; Hoxter G
    Arq Bras Cardiol; 1975 Jun; 28(3):369-77. PubMed ID: 1180718
    [No Abstract]   [Full Text] [Related]  

  • 18. [Isosorbide dinitrate spray: a comparative pharmacodynamic study with a sublingual preparation in patients with chronic cardiac insufficiency].
    Marchionni N; Di Bari M; Ferrucci L; Moschi G; Paoletti M; Salani B; Boncinelli L; Fumagalli S; Schneeweiss A
    Cardiologia; 1988 May; 33(5):505-9. PubMed ID: 3048661
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of a stable form of coronary disease with Adalat retard].
    Kraska T; Korewicki J; Niemczyk M; Opolski G; Jakubowska-Najnigier M; Słomka K; Zieliński T
    Pol Tyg Lek; 1986 Mar; 41(9):277-9. PubMed ID: 3520520
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of isosorbide dinitrate on neutrophil migration in vivo].
    Wysocki H; Siminiak T; Szczepanik A
    Kardiol Pol; 1989; 32(5):255-8. PubMed ID: 2699625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.